About: Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) wüsseschaftlicher Artikel, wo im Johr 2000 veröffentlicht worden isch (gsw) наукова стаття, опублікована в січні 2000 (uk) im Jahr 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 2000 (ast) articolo scientifico (pubblicato il 2000) (it) artikull shkencor i botuar më 01 janar 2000 (sq) scientific article published on 01 January 2000 (en)
publication date	wds:Q73171815-4D9D36A6-FE3B-49C1-BBFC-79298F6CD8BB
publication date	2000-01-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q73171815-04E872C9-13A1-4F23-9D38-05769F127903 wds:Q73171815-07D116C8-986B-40B9-93E6-DEE625A2E3DA wds:Q73171815-0DFA3550-3BA6-43A5-A6B7-1D536E7724C5 wds:Q73171815-3D7F8D72-AD8A-48E2-8F87-49F898A2CBB2 wds:Q73171815-67D2726A-9810-4B34-A15D-75BCD8220BC2 wds:Q73171815-B6811835-8880-40C8-97B0-F8AC2B66D34A wds:Q73171815-EBDF6D80-E1C7-4655-8228-8C118D30D0A4
author name string	Andersson BS Blume KG Tran HT Hu WW Madden T Vaughan WP Chow DS
rdfs:label	Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (en) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (nl) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (sq)
skos:prefLabel	Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (en) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (nl) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (sq)
name	Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (en) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (nl) Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (sq)
author	wds:Q73171815-EDBF12B2-ACB4-4204-8CBA-4EFD91948027
author	Richard E Champlin
title	wds:Q73171815-75D4E97C-D80C-44E5-8621-B0B72D993EDA
title	Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study (en)
page(s)	wds:Q73171815-0D0C6E9A-0FA6-4C4C-B09C-20EB05370D9E
page(s)	548-554
instance of	wds:Q73171815-49EF6CB2-C850-438B-917E-83B3F8C5074C
instance of	scholarly article
main subject	wds:Q73171815-FDF74A69-2BB6-4E67-8C6F-8FE746E10E9C
main subject	pharmacokinetics
PubMed ID	wds:Q73171815-75CE58DA-236A-4648-B904-A4EBE53138F6
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11071260
PubMed ID	11071260
published in	wds:Q73171815-46C9A56B-910A-4FCD-BD0F-4B8672EA1CC4
published in	Biology of Blood and Marrow Transplantation
issue	wds:Q73171815-CC027243-046E-4CD4-A3C5-C2AFF78F201B
volume	wds:Q73171815-54F07BC7-1E65-4026-B6C2-895EE3977A24
issue	5A
volume	6
DOI	wds:Q73171815-C546144C-D8F2-4AB0-80CD-B54593836E9C
DOI	http://dx.doi.org/10.1016/S1083-8791(00)70064-4
DOI	10.1016/S1083-8791(00)70064-4
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73171815
is cites work of	Busulfan in hematopoietic stem cell transplantation Pharmacokinetics of high-dose chemotherapy Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Methodologic guidelines for the design of high-dose chemotherapy regimens Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant Myeloablative conditioning regimens for AML allografts: 30 years later Avoiding hepatic veno-occlusive disease: what do we know and where are we going? Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa) A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity DNA-binding agents Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Pharmacoepidemiology and drug safety Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients Bayesian non-parametric survival regression for optimizing precision dosing of intravenous busulfan in allogeneic stem cell transplantation Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan An LC-MS Assay with Isocratic Separation and On-line Solid Phase Extraction to Improve the Routine Therapeutic Drug Monitoring of Busulfan in Plasma Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software